swissinfo-en

Change is afoot in the upper echelons of Novartis, with Giovanni Caforio set to be elected as the next chair of its board of directors at […]

Zolgensma, a one-off treatment for infants born with a rare and often fatal genetic disease, came to the market five years ago at an eye-watering $2.1 […]

As the global debate intensifies over whether multi-million-dollar drugs are worth the money, big pharma needs to improve transparency over the pricing and therapeutic value of […]

The incoming president of the Federal Institute of Technology Lausanne (EPFL), Anna Fontcuberta i Morral, is concerned about Switzerland’s exclusion from the Horizon Europe research programme, […]